UNSPSC 51282325: Erythromycin propionate

This classification denotes a macrolide antibiotic with the molecular formula C40H71NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HB75CIT999, chemically known as erythromycin, 2-propionate but more generally known as erythromycin propionate, which bears US NIH Compound Identifier 3258. European Medicines Agency schedules Erythromycin propionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01945MIG.

UNSPSC 51282325 Erythromycin propionate, a Commodity code, shows minimal recent activity aligned with its nominal scope. The source contains no active solicitations for erythromycin propionate or closely related pharmaceutical products. A completed award to Chartwell Rx LLC by the Illinois Department of Public Health in August 2026 involved doxycycline hyclate and ciprofloxacin hydrochloride—antibiotics in different classes—rather than erythromycin propionate, which is a macrolide antibiotic used for different clinical indications. A second posted opportunity from Seminole County, Florida in June 2026 sought naloxone and drug deactivation systems, opioid-overdose treatment products unrelated to erythromycin propionate.

The code does not currently show verifiable state and local procurement demand for erythromycin propionate itself. When state and local health departments and counties do procure pharmaceuticals through cooperative purchasing vehicles such as MMCAP or direct IFB, they typically bundle multiple products under a single award or solicit distinct drug classes separately; the recent Illinois contract and Seminole County opportunity reflect this pattern, but neither addresses macrolide antibiotics. Firms evaluating this code should verify whether state and local health systems maintain separate demand signals for erythromycin propionate formulations through their own vendor management systems or formulary procurement channels, as the posted-opportunity record does not substantiate active market activity.